Pharmacological modulation of dopamine receptor D2-mediated transmission alters the metabolic phenotype of diet induced obese and diet resistant C57Bl6 mice

Experimental Diabetes Research

Volumn 2011, Issue , 2011, Pages

  Pijl, H ^a   De Leeuw Van Weenen, J E ^a   Parlevliet, E T ^a   Schrder Van Der Elst, J P ^a   Van Den Berg, S A ^a   Willems Van Dijk, K ^a   Romijn, J A ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; DOPAMINE 2 RECEPTOR; GLUCOSE; HALOPERIDOL; INSULIN; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIET THERAPY; DOPAMINERGIC ACTIVITY; ENERGY EXPENDITURE; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LEAN BODY WEIGHT; LIPID DIET; MALE; MOUSE; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; REINFORCEMENT; TREATMENT DURATION; WEIGHT GAIN; WEIGHT REDUCTION; ANIMAL; ANIMAL BEHAVIOR; BODY WEIGHT; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENERGY METABOLISM; FAT INTAKE; METABOLISM; MOTOR ACTIVITY; MOUSE MUTANT; PHYSIOLOGY; RANDOMIZATION; SYNAPTIC TRANSMISSION;

ANIMALS; BEHAVIOR, ANIMAL; BODY WEIGHT; BROMOCRIPTINE; DIETARY FATS; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; ENERGY METABOLISM; HALOPERIDOL; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; MICE, OBESE; MOTOR ACTIVITY; OBESITY; PHENOTYPE; RANDOM ALLOCATION; RECEPTORS, DOPAMINE D2; SYNAPTIC TRANSMISSION;

EID: 79959269922     PISSN: 16875214     EISSN: 16875303     Source Type: Journal    
DOI: 10.1155/2011/928523     Document Type: Article

References (81)

1. Zhou Q. Y., Palmiter R. D., Dopamine-deficient mice are severely hypoactive, adipsic, and aphagic Cell 1995 83 7 1197 1209 (Pubitemid 26007810)
2. Meguid M. M., Fetissov S. O., Varma M., Sato T., Zhang L., Laviano A., Rossi-Fanelli F., Hypothalamic dopamine and serotonin in the regulation of food intake Nutrition 2000 16 10 843 857
3. Meier A. H., Cincotta A. H., Circadian rhythms regulate the expression of the thrifty genotype/phenotype Diabetes Reviews 1996 4 4 464 487 (Pubitemid 27036135)
4. Nestler E. J., Hard target: understanding dopaminergic neurotransmission Cell 1994 79 6 923 926
5. Yang Z. J., Meguid M. M., LHA dopaminergic activity in obese and lean Zucker rats NeuroReport 1995 6 8 1191 1194
6. Lemierre S., Rouch C., Nicolaidis S., Orosco M., Combined effect of obesity and aging on feeding-induced monoamine release in the rostromedial hypothalamus of the Zucker rat International Journal of Obesity 1998 22 10 993 999 (Pubitemid 28451199)
7. Orosco M., Rough C., Meile M. J., Nicolaidis S., Spontaneous feeding-related monoamine changes in rostromedial hypothalamus of the obese Zucker rat: a microdialysis study Physiology and Behavior 1995 57 6 1103 1106
8. Pijl H., Reduced dopaminergic tone in hypothalamic neural circuits: expression of a thrifty genotype underlying the metabolic syndrome? European Journal of Pharmacology 2003 480 13 125 131 (Pubitemid 37410365)
9. Fetissov S. O., Meguid M. M., Sato T., Zhang LI. H., Expression of dopaminergic receptors in the hypothalamus of lean and obese Zucker rats and food intake American Journal of Physiology 2002 283 4 R905 R910
10. Wang G. J., Volkow N. D., Logan J., Pappas N. R., Wong C. T., Zhu W., Netusll N., Fowler J. S., Brain dopamine and obesity The Lancet 2001 357 9253 354 357 (Pubitemid 32128542)
11. Baptista T., Araujo de Baptista E., Ying Kin N. M. K. NG., Beaulieu S., Walker D., Joober R., Lalonde J., Richard D., Comparative effects of the antipsychotics sulpiride or risperidone in rats. I: bodyweight, food intake, body composition, hormones and glucose tolerance Brain Research 2002 957 1 144 151 (Pubitemid 35346582)
12. Baptista T., Parada M., Hernandez L., Long term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved? Pharmacology Biochemistry and Behavior 1987 27 3 399 405 (Pubitemid 17107006)
13. Newcomer J. W., Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review CNS Drugs 2005 19 1 1 93 (Pubitemid 40677047)
14. Ader M., Kim S. P., Catalano K. J., Ionut V., Hucking K., Richey J. M., Kabir M., Bergman R. N., Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs Diabetes 2005 54 3 862 871 (Pubitemid 40322092)
15. Pijl H., Ohashi S., Matsuda M., Miyazaki Y., Mahankali A., Kumar V., Pipek R., Iozzo P., Lancaster J. L., Cincotta A. H., DeFronzo R. A., Bromocriptine: a novel approach to the treatment of type 2 diabetes Diabetes Care 2000 23 8 1154 1161 (Pubitemid 30616805)
16. Kuo D. Y., Co-administration of dopamine D and D agonists additively decreases daily food intake, body weight and hypothalamic neuropeptide Y level in rats Journal of Biomedical Science 2002 9 2 126 132
17. Luo S., Liang Y., Cincotta A. H., Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant/glucose-intolerant state in hamsters Neuroendocrinology 1999 69 3 160 166 (Pubitemid 29134491)
18. Kok P., Roelfsema F., Frlich M., Van Pelt J., Stokkel M. P. M., Meinders A. E., Pijl H., Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women American Journal of Physiology 2006 291 5 E1038 E1043
19. Chang S., Graham B., Yakubu F., Lin D., Peters J. C., Hill J. O., Metabolic differences between obesity-prone and obesity-resistant rats American Journal of Physiology 1990 259 6, part 2 R1103 R1110
20. Burcelin R., Crivelli V., Dacosta A., Roy-Tirelli A., Thorens B., Heterogeneous metabolic adaptation of C57BL/6J mice to high-fat diet American Journal of Physiology 2002 282 4 E834 E842
21. Huang X. F., Han M., Storlien L. H., The level of NPY receptor mRNA expression in diet-induced obese and resistant mice Molecular Brain Research 2003 115 1 21 28 (Pubitemid 36725032)
22. Clegg D. J., Benoit S. C., Reed J. A., Woods S. C., Dunn-Meynell A., Levin B. E., Reduced anorexic effects of insulin in obesity-prone rats fed a moderate-fat diet American Journal of Physiology 2005 288 4 R981 R986
23. Huang X. F., Zavitsanou K., Huang X., Yu Y., Wang H., Chen F., Lawrence A. J., Deng C., Dopamine transporter and D receptor binding densities in mice prone or resistant to chronic high fat diet-induced obesity Behavioural Brain Research 2006 175 2 415 419 (Pubitemid 44750233)
24. Levin B. E., Dunn-Meynell A. A., Dysregulation of arcuate nucleus preproneuropeptide Y mRNA in diet- induced obese rats American Journal of Physiology 1997 272 5 R1365 R1370
25. McLean J. A., Tobin G., Animal and Human Calorimetry 1987 Cambridge, UK Cambridge University Press
26. Voshol P. J., Jong M. C., Dahlmans V. E. H., Kratky D., Levak-Frank S., Zechner R., Romijn J. A., Havekes L. M., In muscle-specific lipoprotein lipase-overexpressing mice, muscle triglyceride content is increased without inhibition of insulin-stimulated whole-body and muscle-specific glucose uptake Diabetes 2001 50 7-12 2585 2590 (Pubitemid 33642778)
27. Leibowitz K. L., Chang G. Q., Pamy P. S., Hill J. O., Gayles E. C., Leibowitz S. F., Weight gain model in prepubertal rats: prediction and phenotyping of obesity-prone animals at normal body weight International Journal of Obesity 2007 31 8 1210 1221 (Pubitemid 47172624)
28. Van Den Hoek A. M., Voshol P. J., Karnekamp B. N., Buijs R. M., Romijn J. A., Havekes L. M., Pijl H., Intracerebroventricular neuropeptide Y infusion precludes inhibition of glucose and VLDL production by insulin Diabetes 2004 53 10 2529 2534 (Pubitemid 39299258)
29. Poca A., Lam T. K., Gutierrez-Juarez R., Obici S., Schwartz G. J., Bryan J., Aguilar-Bryan L., Rossetti L., Hypothalamic K channels control hepatic glucose production Nature 2005 434 7036 1026 1031 (Pubitemid 40586051)
30. Cincotta A. H., Tozzo E., Scislowski P. W. D., Bromocriptine/SKF38393 treatment ameliorates obesity and associated metabolic dysfunctions in obese (ob/ob) mice Life Sciences 1997 61 10 951 956 (Pubitemid 27348663)
31. Schmidt A. W., Lebel L. A., Howard H. R., Zorn S. H., Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile European Journal of Pharmacology 2001 425 3 197 201 (Pubitemid 32770067)
32. Millan M. J., Maiofiss L., Cussac D., Audinot V., Boutin J. A., Newman-Tancredi A., Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes Journal of Pharmacology and Experimental Therapeutics 2002 303 2 791 804 (Pubitemid 35231256)
33. Lhdesmki J., Sallinen J., MacDonald E., Sirvi J., Scheinin M., -adrenergic drug effects on brain monoamines, locomotion, and body temperature are largely abolished in mice lacking the -adrenoceptor subtype Neuropharmacology 2003 44 7 882 892 (Pubitemid 36515024)
34. Ostenson C. G., Cattaneo A. G., Doxey J. C., Efendic S., -Adrenoceptors and insulin release from pancreatic islets of normal and diabetic rats American Journal of Physiology 1989 257 3, part 1 E439 E443
35. Peterhoff M., Sieg A., Brede M., Chao C. M., Hein L., Ullrich S., Inhibition of insulin secretion via distinct signaling pathways in -adrenoceptor knockout mice European Journal of Endocrinology 2003 149 4 343 350 (Pubitemid 37304706)
36. de Leeuw van Weenen J. E., Parlevliet E. T., Maechler P., Havekes L. M., Romijn J. A., Ouwens D. M., Pijl H., Guigas B., The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the 2-adrenergic receptors in beta cells Biochemical Pharmacology 2010 79 12 1827 1836
37. Devedjian J. C., Pujol A., Cayla C., George M., Casellas A., Paris H., Bosch F., Transgenic mice overexpressing (2A)-adrenoceptors in pancreatic beta- cells show altered regulation of glucose homeostasis Diabetologia 2000 43 7 899 906 (Pubitemid 30463170)
38. Hutchinson D. S., Bengtsson T., -adrenoceptors activate glucose uptake in L6 muscle cells through a phospholipase C-, phosphatidylinositol-3 kinase-, and atypical protein kinase C-dependent pathway Endocrinology 2005 146 2 901 912 (Pubitemid 40129848)
39. Faintrenie G., Glon A., Alpha-1 adrenergic stimulation of glucose uptake in rat white adipocytes Journal of Pharmacology and Experimental Therapeutics 1998 286 2 607 610 (Pubitemid 29003445)
40. Flechtner-Mors M., Jenkinson C. P., Alt A., Biesalski H. K., Adler G., Ditschuneit H. H., Sympathetic regulation of glucose uptake by the -adrenoceptor in human obesity Obesity Research 2004 12 4 612 620 (Pubitemid 41132503)
41. Burcelin R., Uldry M., Foretz M., Perrin C., Dacosta A., Nenniger-Tosato M., Seydoux J., Cotecchia S., Thorens B., Impaired glucose homeostasis in mice lacking the -adrenergic receptor subtype Journal of Biological Chemistry 2004 279 2 1108 1115 (Pubitemid 38082632)
42. Hutson P. H., Dourish C. T., Curzon G., Evidence that the hyperphagic response to 8-OH-DPAT is mediated by 5-HT(1A) receptors European Journal of Pharmacology 1988 150 3 361 366
43. Lam D. D., Heisler L. K., Serotonin and energy balance: molecular mechanisms and implications for type 2 diabetes Expert Reviews in Molecular Medicine 2007 9 5 1 24 (Pubitemid 46358401)
44. Chaouloff F., Jeanrenaud B., 5-HT(1A) and alpha-2 adrenergic receptors mediate the hyperglycemic and hypoinsulinemic effects of 8-hydroxy-2-(di-n- propylamino)tetralin in the conscious rat Journal of Pharmacology and Experimental Therapeutics 1987 243 3 1159 1166 (Pubitemid 18017175)
45. Uvns-Moberg K., Ahlenius S., Alster P., Hillegaart V., Effects of selective serotonin and dopamine agonists on plasma levels of glucose, insulin and glucagon in the rat Neuroendocrinology 1996 63 3 269 274 (Pubitemid 26070812)
46. Buse J. B., Cavazzoni P., Hornbuckle K., Hutchins D., Breier A., Jovanovic L., A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States Journal of Clinical Epidemiology 2003 56 2 164 170 (Pubitemid 36315943)
47. Allison D. B., Mentore J. L., Heo M., Chandler L. P., Cappelleri J. C., Infante M. C., Weiden P. J., Antipsychotic-induced weight gain: a comprehensive research synthesis American Journal of Psychiatry 1999 156 11 1686 1696 (Pubitemid 29517559)
48. Simn V. M., Parra A., Miarro J., Arenas M. C., Vinader-Caerols C., Aguilar M. A., Predicting how equipotent doses of chlorpromazine, haloperidol, sulpiride, raclopride and clozapine reduce locomotor activity in mice European Neuropsychopharmacology 2000 10 3 159 164 (Pubitemid 30227615)
49. Wiley J. L., Evans R. L., Evaluation of age and sex differences in locomotion and catalepsy during repeated administration of haloperidol and clozapine in adolescent and adult rats Pharmacological Research 2008 58 3-4 240 246
50. Stuart C. A., Shangraw R. E., Prince M. J., Peters E. J., Wolfe R. R., Bed-rest-induced insulin resistance occurs primarily in muscle Metabolism: Clinical and Experimental 1988 37 8 802 806
51. Alibegovic A. C., Hjbjerre L., Sonne M. P., Van Hall G., Stallknecht B., Dela F., Vaag A., Impact of 9 days of bed rest on hepatic and peripheral insulin action, insulin secretion, and whole-body lipolysis in healthy young male offspring of patients with type 2 diabetes Diabetes 2009 58 12 2749 2756
52. Hruska R. E., Modulatory role for prolactin in the elevation of striatal dopamine receptor density induced by chronic treatment with dopamine receptor antagonists Brain Research Bulletin 1986 16 3 331 339 (Pubitemid 16071490)
53. Xu R., Parlow A. F., Wang Y., The effects of dopamine and D2 receptor antagonists on pituitary hormone secretion are intact in mice lacking dopamine D2L receptor Brain Research 2002 939 1-2 95 99 (Pubitemid 34518593)
54. Gustafson A. B., Banasiak M. F., Kalkhoff R. K., Correlation of hyperprolactinemia with altered plasma insulin and glucagon: similarity to effects of late human pregnancy Journal of Clinical Endocrinology and Metabolism 1980 51 2 242 246 (Pubitemid 10007626)
55. Tuzcu A., Yalaki S., Arikan S., Gokalp D., Bahcec M., Tuzcu S., Evaluation of insulin sensitivity in hyperprolactinemic subjects by euglycemic hyperinsulinemic clamp technique Pituitary 2009 12 4 330 334
56. Perez-Iglesias R., Vazquez-Barquero J. L., Amado J. A., Berja A., Garcia-Unzueta M. T., Pelayo-Tern J. M., Carrasco-Marn E., Mata I., Crespo-Facorro B., Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment Journal of Clinical Psychopharmacology 2008 28 3 289 295
57. Kraus T., Haack M., Schuld A., Hinze-Selch D., Khn M., Uhr M., Pollmcher T., Body weight and leptin plasma levels during treatment with antipsychotic drugs American Journal of Psychiatry 1999 156 2 312 314 (Pubitemid 29077125)
58. von Wilmsdorff M., Bouvier M.-L., Henning U., Schmitt A., Gaebel W., The impact of antipsychotic drugs on food intake and body weight and on leptin levels in blood and hypothalamic ob-r leptin receptor expression in wistar rats Clinics 2010 65 9 885 894
59. Van Den Hoek A. M., Teusink B., Voshol P. J., Havekes L. M., Romijn J. A., Pijl H., Leptin deficiency per se dictates body composition and insulin action in ob/ob mice Journal of Neuroendocrinology 2008 20 1 120 127 (Pubitemid 350239156)
60. Heijboer A. C., Van Den Hoek A. M., Parlevliet E. T., Havekes L. M., Romijn J. A., Pijl H., Corssmit E. P. M., Ghrelin differentially affects hepatic and peripheral insulin sensitivity in mice Diabetologia 2006 49 4 732 738 (Pubitemid 43357547)
61. Melkersson K., Khan A., Hilding A., Hulting A. L., Different effects of antipsychotic drugs on insulin release in vitro European Neuropsychopharmacology 2001 11 5 327 332 (Pubitemid 32946882)
62. Garca-Tornad I., Ornstein A. M., Chamson-Reig A., Wheeler M. B., Hill D. J., Arany E., Rubinstein M., Becu-Villalobos D., Disruption of the dopamine D2 receptor impairs insulin secretion and causes glucose intolerance Endocrinology 2010 151 4 1441 1450
63. Henry R. R., Glucose control and insulin resistance in non-insulin-dependent diabetes mellitus Annals of Internal Medicine 1996 124 1, part 2 97 103 (Pubitemid 26011604)
64. Carey R. M., Van Loon G. R., Baines A. D., Kaiser D. L., Suppression of basal and stimulated noradrenergic activities by the dopamine agonist bromocriptine in man Journal of Clinical Endocrinology and Metabolism 1983 56 3 595 602 (Pubitemid 13157811)
65. Durant S., Coulaud J., Homo-Delarche F., Bromocriptine-induced hyperglycemia in nonobese diabetic mice: kinetics and mechanisms of action Review of Diabetic Studies 2007 4 3 185 194
66. Luo S., Meier A. H., Cincotta A. H., Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters Neuroendocrinology 1998 68 1 1 10 (Pubitemid 28310603)
67. Scislowski P. W.D., Tozzo E., Zhang Y., Phaneuf S., Prevelige R., Cincotta A. H., Biochemical mechanisms responsible for the attenuation of diabetic and obese conditions in ob/ob mice treated with dopaminergic agonists International Journal of Obesity 1999 23 4 425 431 (Pubitemid 29182403)
68. Cincotta A. H., Meier A. H., Cincotta M., Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes Expert Opinion on Investigational Drugs 1999 8 10 1683 1707 (Pubitemid 29460532)
69. Yavuz D., Deyneli O., Akpinar I., Yildiz E., Gz H., Sezgin.., Haklar G., Akalin S., Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women European Journal of Endocrinology 2003 149 3 187 193 (Pubitemid 37120990)
70. dos Santos Silva C. M., Barbosa F. R., Lima G. A., Warszawski L., Fontes R., Domingues R. C., Gadelha M. R., BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists Obesity 2011 19 4 800 805
71. Chiba T., Chihara K., Minamitani N., Effect of long term bromocriptine treatment on glucose intolerance in acromegaly Hormone and Metabolic Research 1982 14 2 57 61 (Pubitemid 12166837)
72. Hainer V., Zak A., Sindelkova E., Elevation of high density lipoproteins in acromegalics after lisuride treatment Hormone and Metabolic Research 1985 17 4 220 221 (Pubitemid 15062952)
73. Rau H., Althoff P. H., Schmidt K., Badenhoop K., Usadel K. H., Bromocriptine treatment over 12 years in acromegaly: effect on glucose tolerance and insulin secretion Clinical Investigator 1993 71 5 372 378 (Pubitemid 23142836)
74. Nirenberg M. J., Waters C., Compulsive eating and weight gain related to dopamine agonist use Movement Disorders 2006 21 4 524 529
75. Weintraub D., Koester J., Potenza M. N., Siderowf A. D., Stacy M., Voon V., Whetteckey J., Wunderlich G. R., Lang A. E., Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients Archives of Neurology 2010 67 5 589 595
76. Cincotta A. H., Meier A. H., Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters (Mesocricetus auratus) Metabolism: Clinical and Experimental 1995 44 10 1349 1355 (Pubitemid 26087799)
77. Song S. H., Rhodes C. J., Veldhuis J. D., Butler P. C., Diazoxide attenuates glucose-induced defects in first-phase insulin release and pulsatile insulin secretion in human islets Endocrinology 2003 144 8 3399 3405 (Pubitemid 36904415)
78. Leahy J. L., Bumbalo L. M., Chen C., Diazoxide causes recovery of -cell glucose responsiveness in 90 pancreatectomized diabetic rats Diabetes 1994 43 2 173 179 (Pubitemid 24033669)
79. Alemzadeh R., Slonim A. E., Zdanowicz M. M., Maturo J., Modification of insulin resistance by diazoxide in obese Zucker rats Endocrinology 1993 133 2 705 712 (Pubitemid 23238883)
80. Alemzadeh R., Holshouser S., Effect of diazoxide on brain capillary insulin receptor binding and food intake in hyperphagic obese Zucker rats Endocrinology 1999 140 7 3197 3202 (Pubitemid 30650637)
81. Kok P., Roelfsema F., Frlich M., Van Pelt J., Meinders A. E., Pijl H., Activation of dopamine D2 receptors lowers circadian leptin concentrations in obese women Journal of Clinical Endocrinology and Metabolism 2006 91 8 3236 3240 (Pubitemid 44271783)